PALIPERIDONE PALMITATE
| Brand name | INVEGA HAFYERA |
|---|---|
| Active ingredient | PALIPERIDONE PALMITATE |
| Strength | 1.092GM/3.5ML (312MG/ML) |
| Dosage form | SUSPENSION, EXTENDED RELEASE |
| Route | INTRAMUSCULAR |
| Modality | Small molecule |
| FDA approval | August 2021 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11666697 | November 2041 | use U-3626 |
| 11324751 | May 2041 | use U-3359 |
| 11304951 | May 2041 | use U-3349 |
| 12208100 | May 2041 | use U-4110 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.